We are live on !
Find out more
Lite Strategy Inc
LITS
LITS
About: Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
Employees: 5
News
Positive
Neutral
Negative
Sentiment
3-Months
Positive
0%
Neutral
100%
Negative
0%
Price charts implemented using Lightweight Charts™